 |
Photo = Samsung Bioepis |
[Alpha Biz= Kim Jisun] Seoul, South Korea – May 25, 2025 – Samsung Bioepis has firmly denied speculation regarding a potential dual listing, following the recent announcement by Samsung Biologics to establish Samsung Epys Holdings through a company split.
According to industry sources, Samsung Bioepis reaffirmed on May 22—during an internal briefing held on the day of the announcement—that it has no plans for a public listing. This message was shared directly with employees to dispel any uncertainty surrounding the company’s future direction.
On the same day, Samsung Biologics announced its decision to separate its businesses into two independent entities: contract development and manufacturing organization (CDMO) operations and biosimilar development. The move aims to address potential concerns from CDMO clients over competitive overlap and to resolve the investment dilemma faced by stakeholders evaluating two fundamentally different business models under one roof.
Under the restructuring plan, the division responsible for managing subsidiaries and new investments will be spun off to create Samsung Epys Holdings. As a result, Samsung Bioepis will become a wholly owned subsidiary of the newly formed holding company, effective October 1, 2025.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
